ATE275422T1 - Konjugate aus polyole und beta-interferon - Google Patents

Konjugate aus polyole und beta-interferon

Info

Publication number
ATE275422T1
ATE275422T1 AT99920094T AT99920094T ATE275422T1 AT E275422 T1 ATE275422 T1 AT E275422T1 AT 99920094 T AT99920094 T AT 99920094T AT 99920094 T AT99920094 T AT 99920094T AT E275422 T1 ATE275422 T1 AT E275422T1
Authority
AT
Austria
Prior art keywords
conjugates
interferon
polyols
beta
Prior art date
Application number
AT99920094T
Other languages
English (en)
Inventor
Tayar Nabil El
Michael J Roberts
Milton Harris
Wayne Sawlivich
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE275422T1 publication Critical patent/ATE275422T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99920094T 1998-04-28 1999-04-28 Konjugate aus polyole und beta-interferon ATE275422T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28
PCT/US1999/009161 WO1999055377A2 (en) 1998-04-28 1999-04-28 Polyol-ifn-beta conjugates

Publications (1)

Publication Number Publication Date
ATE275422T1 true ATE275422T1 (de) 2004-09-15

Family

ID=22177687

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04003053T ATE365563T1 (de) 1998-04-28 1999-04-28 Verfahren zur schrittweise bindung von polyethylenglykol (peg) an polypeptide
AT99920094T ATE275422T1 (de) 1998-04-28 1999-04-28 Konjugate aus polyole und beta-interferon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04003053T ATE365563T1 (de) 1998-04-28 1999-04-28 Verfahren zur schrittweise bindung von polyethylenglykol (peg) an polypeptide

Country Status (30)

Country Link
US (3) US6638500B1 (de)
EP (2) EP1421956B1 (de)
JP (2) JP4574007B2 (de)
KR (1) KR100622796B1 (de)
CN (2) CN1187094C (de)
AR (1) AR020070A1 (de)
AT (2) ATE365563T1 (de)
AU (1) AU762621B2 (de)
BG (2) BG64694B1 (de)
BR (1) BR9910023A (de)
CA (2) CA2330451A1 (de)
CY (1) CY1108022T1 (de)
CZ (2) CZ298579B6 (de)
DE (2) DE69936409T2 (de)
DK (2) DK1075281T3 (de)
EA (2) EA003789B1 (de)
EE (1) EE05214B1 (de)
ES (2) ES2285286T3 (de)
HU (1) HUP0300548A3 (de)
IL (1) IL139286A (de)
NO (2) NO329749B1 (de)
NZ (1) NZ507456A (de)
PL (2) PL193352B1 (de)
PT (2) PT1421956E (de)
SI (2) SI1075281T1 (de)
SK (2) SK286654B6 (de)
TR (2) TR200101751T2 (de)
TW (2) TWI266800B (de)
UA (2) UA66857C2 (de)
WO (1) WO1999055377A2 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
AU766190B2 (en) 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
HUP0201425A3 (en) * 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
TR200101086A3 (de) * 1999-10-15 2001-08-21
US7691367B2 (en) 1999-12-24 2010-04-06 Kyowa Hakko Kirin Co., Ltd. Branched polyalkylene glycols
HUP0203751A3 (en) 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
CA2436623C (en) * 2001-01-30 2011-08-02 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
EP1234583A1 (de) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-Konjugate des HGF-NK4
EP1366075B1 (de) 2001-02-27 2009-05-27 Maxygen Aps Neue interferon-beta-ähnliche moleküle
KR100961859B1 (ko) 2001-07-11 2010-06-09 맥시겐 홀딩스 엘티디 지-씨에스에프 접합체
PT3025726T (pt) 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
RS20050501A (sr) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora
GEP20084486B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
EP2085470B1 (de) 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII oder FVIIa Varianten
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
EP1586334A1 (de) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF Konjugate mit PEG
US7879320B2 (en) 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
US7731948B2 (en) 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
EA012281B1 (ru) 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
JP5243041B2 (ja) * 2004-12-21 2013-07-24 ネクター セラピューティックス 安定化ポリマーチオール試薬
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
BRPI0614257A2 (pt) * 2005-08-04 2011-03-15 Nektar Therapeutics Al Corp conjugados de uma porção de g-csf e um polìmero
US20080219952A1 (en) 2005-08-26 2008-09-11 Ares Trading S.A. Process For the Preparation of Glycosylated Interferon Beta
EP1933860A2 (de) 2005-09-01 2008-06-25 Ares Trading S.A. Behandlung von optikusneuritis
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
CA2653748A1 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
AU2007253264A1 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Factor IX analogues having prolonged in vivo half life
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
RS52417B (sr) 2007-12-20 2013-02-28 Merck Serono S.A. Formulacije peg-interferona-beta
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
EP2536753B1 (de) 2010-02-16 2017-12-20 Novo Nordisk A/S Faktor-VIII-Moleküle mit reduzierter VWF-Bindung
EP4450523A3 (de) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsprotein-arzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
EP2569331A1 (de) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptid-inhibitoren von vla4
JP2013532176A (ja) 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
CN104788557A (zh) 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
IN2014CN02982A (de) * 2011-10-01 2015-07-03 Glytech Inc
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US20150030564A1 (en) 2012-02-29 2015-01-29 Toray Industries, Inc. Inhibitory agent for body cavity fluid accumulation
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
AU2014245917B2 (en) 2013-03-29 2017-09-28 Glytech, Inc. Polypeptide having sialylated sugar chains attached thereto
US11759500B2 (en) 2014-07-24 2023-09-19 Abion Inc. PEGylated interferon-beta variant
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
SI3183264T1 (sl) 2014-08-19 2021-03-31 Biogen Ma Inc. Metoda pegilacije
ES2903448T3 (es) 2015-05-01 2022-04-01 Allysta Pharmaceuticals Inc Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares
EP3795591B1 (de) * 2015-06-19 2023-09-27 Eisai R&D Management Co., Ltd. Cys80-konjugierte immunglobuline
DK3998067T3 (da) 2015-11-09 2024-10-28 Univ Colorado Regents Sammensætninger og fremgangsmåder til behandling af homocystinuri
CA3059592A1 (en) * 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
CN113382775A (zh) 2019-01-28 2021-09-10 东丽株式会社 肝细胞生长因子或其活性片段的聚乙二醇修饰物
EP3919128A4 (de) 2019-01-28 2023-01-11 Toray Industries, Inc. Polyethylenglykolmodifizierter körper für hepatorytenwachstumsfaktor oder aktives fragment davon
IL301246A (en) 2020-09-10 2023-05-01 Merck Patent Gmbh Treatment regimen with cladribine

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229108B1 (de) * 1985-06-26 1990-12-27 Cetus Corporation Solubilisierung von proteinen für pharmazeutische zusammensetzungen mittels polymerkonjugierung
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
EE9600121A (et) 1994-03-31 1997-04-15 Amgen Inc. Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid
AU696387B2 (en) * 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
AU5773798A (en) * 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
EA005495B1 (ru) 2005-02-24
UA79430C2 (en) 2007-06-25
TR200003161T2 (tr) 2001-01-22
UA66857C2 (uk) 2004-06-15
BG109291A (en) 2006-04-28
AU762621B2 (en) 2003-07-03
ATE365563T1 (de) 2007-07-15
NO20005337L (no) 2000-12-28
NO20005337D0 (no) 2000-10-23
HUP0300548A3 (en) 2005-07-28
IL139286A0 (en) 2001-11-25
CZ20003995A3 (en) 2001-06-13
JP2010184929A (ja) 2010-08-26
CZ298579B6 (cs) 2007-11-14
BG65046B1 (bg) 2007-01-31
HK1076115A1 (zh) 2006-01-06
JP2002512983A (ja) 2002-05-08
PL193352B1 (pl) 2007-02-28
CA2565375A1 (en) 1999-11-04
EE05214B1 (et) 2009-10-15
EP1075281B1 (de) 2004-09-08
EP1421956B1 (de) 2007-06-27
DE69936409D1 (de) 2007-08-09
BG64694B1 (bg) 2005-12-30
DK1075281T3 (da) 2005-01-03
HUP0300548A2 (hu) 2003-06-28
US20070141620A1 (en) 2007-06-21
SK286654B6 (sk) 2009-03-05
EA200300382A1 (ru) 2005-02-24
CN1187094C (zh) 2005-02-02
US6638500B1 (en) 2003-10-28
BR9910023A (pt) 2000-12-26
SK286217B6 (sk) 2008-05-06
NO20100324L (no) 2000-12-28
NO329749B1 (no) 2010-12-13
CN100335503C (zh) 2007-09-05
DK1421956T3 (da) 2007-10-01
AR020070A1 (es) 2002-04-10
PT1421956E (pt) 2007-07-13
HK1038194A1 (zh) 2002-03-08
BG104871A (bg) 2001-07-31
CZ298597B6 (cs) 2007-11-21
TWI232882B (en) 2005-05-21
NZ507456A (en) 2003-10-31
TR200101751T2 (tr) 2002-05-21
ES2224649T3 (es) 2005-03-01
TWI266800B (en) 2006-11-21
EA200001111A1 (ru) 2001-04-23
ES2285286T3 (es) 2007-11-16
DE69920002D1 (de) 2004-10-14
EE200000614A (et) 2002-04-15
KR100622796B1 (ko) 2006-09-13
SK16222000A3 (sk) 2001-04-09
WO1999055377A2 (en) 1999-11-04
IL139286A (en) 2005-12-18
US7357925B2 (en) 2008-04-15
WO1999055377A3 (en) 1999-12-29
PT1075281E (pt) 2004-11-30
CN1302209A (zh) 2001-07-04
AU3767499A (en) 1999-11-16
EA003789B1 (ru) 2003-10-30
SI1075281T1 (en) 2005-02-28
US7700314B2 (en) 2010-04-20
EP1075281A2 (de) 2001-02-14
CA2330451A1 (en) 1999-11-04
EP1421956A1 (de) 2004-05-26
NO332224B1 (no) 2012-07-30
WO1999055377A9 (en) 2000-03-02
CN1637020A (zh) 2005-07-13
PL344490A1 (en) 2001-11-05
JP4574007B2 (ja) 2010-11-04
US20040043002A1 (en) 2004-03-04
KR20010071158A (ko) 2001-07-28
DE69936409T2 (de) 2008-04-17
CY1108022T1 (el) 2013-09-04
SI1421956T1 (sl) 2007-10-31
PL196533B1 (pl) 2008-01-31
DE69920002T2 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
DE69920002D1 (de) Konjugate aus polyole und beta-interferon
DE69932265D1 (de) Musikaktionsspielsystem und computerlesbare Aufzeichnungsvorrichtung
DE69913169D1 (de) Sportschuh und dafür vorgesehene dornen
DE69911378D1 (de) Fluorierte ionomere und verwendung davon
ATE480590T1 (de) Rheologieveränderte thermoplastische elastomerzusammensetzungen und gegenstände daraus
ATE252832T1 (de) Kombinationen aus herbiziden und safenern
DE69919446D1 (de) Absorbierender Artikel
DE69936037D1 (de) Absorbierender Artikel
DE69919253D1 (de) Absorbierender Artikel
DE69918233D1 (de) Polymilchsäure zusammensetzung und daraus hergestellter film
DE69921723D1 (de) USB-Vorrichtung und USB- Knotenpunktvorrichtung
DE69901853D1 (de) Luftsack und Luftsackvorrichtung
NO20032753L (no) Forbindelse og anvendelse derav
ATE357252T1 (de) Adjuvanzsysteme und impfstoffe
DE69941968D1 (de) Absorbierender Artikel
DE69927261D1 (de) Absorbierender Artikel
DE69937418D1 (de) Harzzusammensetzung und Harzfolie
NO20006488D0 (no) Sammensetning og anvendelse
DE60009632D1 (de) Toner und Tonerharzzusammensetzung
DE69836329D1 (de) Schneller und hochverstärkender operationsverstärker
DE60034067D1 (de) Pfropfcopolymer und thermoplastische harzzusammensetzung
ATE227724T1 (de) Muscarinagonisten und antagonisten
DE10084522T1 (de) Hautfreundliche absorptionsfähige Artikel und Zusammensetzungen
DE69939139D1 (de) Aufzeichnungsgerät und Blattmaterialfördergerät
DE69911152D1 (de) Symmetrischer Verstärker

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1075281

Country of ref document: EP

EEFA Change of the company name